Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of tolvaptan versus standard medical management, placebo, or other vaptans for the treatment of hyponatraemia in people with cirrhosis.
Authors
- Zubair Umer Mohamed (ORCID: https://orcid.org/0000-0002-0409-9066)
- N Saraswathy
- ST Binoj
- Christi Titus Varghese (ORCID: https://orcid.org/0000-0001-6852-2516)
- K N Anila (ORCID: https://orcid.org/0000-0003-2593-9623)
- Arun Valsan (ORCID: https://orcid.org/0000-0002-8410-9665)
- Dinesh Balakrishnan
- Surendran Sudhindran (ORCID: https://orcid.org/0000-0002-3973-7697)
- Unnikrishnan Gopalakrishnan
Institutions
- Amrita Institute of Medical Sciences and Research Centre (IN)
Publication Details
- Journal
- Cochrane Database of Systematic Reviews
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1002/14651858.cd016218
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rigshospitalet